AIS
TNYA icon

Accredited Investor Services’s Tenaya Therapeutics TNYA Stock Holding History

Accredited Investor Services’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,000
Closed -$21.4K – 96
2024
Q4 		$21.4K Buy
+15,000
New +$33.6K 0.02% 57

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Accredited Investor Services's TNYA Position: Q1 2025 in Review

Accredited Investor Services sold out of Tenaya Therapeutics (TNYA) in Q1 2025, closing a stake of 15,000 shares — an estimated $21.4K sold.

Accredited Investor Services first reported a position in TNYA in Q4 2024 and held it in 1 quarter. The position peaked at $21.4K in Q4 2024. 107 funds tracked by Wall St. Rank hold TNYA as of Q1 2025.

  • Accredited Investor Services reported no remaining Tenaya Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Accredited Investor Services sold 15,000 Tenaya Therapeutics shares in Q1 2025, an estimated $21.4K.
  • Accredited Investor Services first reported a position in Tenaya Therapeutics in Q4 2024 and held it in 1 quarter.
  • Accredited Investor Services's Tenaya Therapeutics position peaked at $21.4K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2025.

Based on Accredited Investor Services's 13F filing for Q1 2025, filed 2 May 2025.